Evidence map›Paper›PMID 24748470›Full record

ArticleJournal of neuro-oncology2014

IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.

Giuseppe Minniti, Claudia Scaringi, Antonella Arcella, Gaetano Lanzetta, Domenica Di Stefano, Stefania Scarpino, Alessandro Bozzao, Andrea Pace, Veronica Villani, Maurizio Salvati and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 4 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.Archives of pathology & laboratory medicine · 2022
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Giuseppe MinnitiRadiation Oncology Unit, Sant'Andrea Hospital, University Sapienza, Via di Grottarossa 1035, 00189, Rome, Italy. giuseppe.minniti@ospedalesantandrea.it.
Claudia ScaringiRadiation Oncology Unit, Sant'Andrea Hospital, University Sapienza, Via di Grottarossa 1035, 00189, Rome, Italy.
Antonella ArcellaIRCCS Neuromed, Pozzilli, IS, Italy.
Gaetano LanzettaIRCCS Neuromed, Pozzilli, IS, Italy.
Domenica Di StefanoPathology Unit, Sant'Andrea Hospital, University Sapienza, Rome, Italy.
Stefania ScarpinoPathology Unit, Sant'Andrea Hospital, University Sapienza, Rome, Italy.
Alessandro BozzaoNeuroradiology Unit, Sant'Andrea Hospital, University Sapienza, Rome, Italy.
Andrea PaceNeurology Unit, Regina Elena Institute, Rome, Italy.
Veronica VillaniNeurology Unit, Regina Elena Institute, Rome, Italy.
Maurizio SalvatiNeurosurgery Unit, Policlinico Umberto I, University Sapienza, Rome, Italy.
Vincenzo EspositoIRCCS Neuromed, Pozzilli, IS, Italy.
Felice GiangasperoIRCCS Neuromed, Pozzilli, IS, Italy.
Riccardo Maurizi EnriciRadiation Oncology Unit, Sant'Andrea Hospital, University Sapienza, Via di Grottarossa 1035, 00189, Rome, Italy.
Azienda Ospedaliera Sant'Andrea · ITIstituto Neurologico Mediterraneo · ITDeutsches Historisches Institut Rom · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several molecular markers have been proposed as predictors of outcome in patients with high grade gliomas. We report a retrospective multicenter study of 97 consecutive adult patients with anaplastic astrocytoma (AA) treated with radiation therapy (RT) plus concomitant and adjuvant temozolomide (TMZ) between October 2004 and March 2012. Correlations between the isocitrate dehydrogenase 1 (IDH1) mutation and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with survival outcomes have been analyzed. At a median follow-up time of 46 months (range 12-89 months), median and 5-year overall survival rates were 50.5 months (95 % CI, 37.8-63.2) and 38% (95 % CI, 25.7-50.7%), and median and 5-year progression-free survival rates were 36 months (95% CI, 28.5-44.0) and 22 % (95 % CI, 10-34%), respectively. IDH1 mutation and MGMT promoter methylation were present in 54 and 60% of evaluable patients, respectively. Multivariate Cox proportional hazards regression analysis showed that IDH1 mutation (P = 0.001), MGMT methylation (P = 0.01), age < 50 years (P = 0.02), and extent of resection (P = 0.04) were significantly associated with longer survival. Our study confirms the favorable prognostic value of IDH1 mutation and MGMT methylation in patients with AA treated with RT plus concomitant and adjuvant TMZ. The superiority of combined radiochemotherapy over other treatment modalities remains to be demonstrated.

Indexed as

ChemoradiotherapyAdultAgedAntineoplastic Agents, AlkylatingAstrocytomaBiomarkersBrain NeoplasmsDacarbazineDNA MethylationDNA Modification MethylasesDNA Repair EnzymesFemaleFollow-Up StudiesHumansIsocitrate DehydrogenaseMaleAntineoplastic Agents, AlkylatingBiomarkersDacarbazineDNA Modification MethylasesDNA Repair EnzymesIDH1 protein, humanIsocitrate DehydrogenaseMGMT protein, humanTemozolomideTumor Suppressor Proteins

Identifiers

PMID24748470
OpenAlexW1973864599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.